Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be ...

Signed into law as part of the Consolidated Appropriations Act of 2023, the NOPAIN Act sought to prevent opioid addiction by increasing access to qualifying non-opioid pain management options for ...

Pacira BioSciences PCRX reported fourth-quarter 2024 adjusted earnings of 91 cents per share, which beat the Zacks Consensus Estimate of 86 cents. The company had reported adjusted earnings of 89 ...

Objectives To determine the prevalence of proximal deep vein thrombosis (DVT) by ultrasound scanning, as well as associated clinical features and known risk factors, among medical and ...

3 Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China Background Tuina demonstrates clinical therapeutic efficacy in the treatment of knee osteoarthritis (KOA).

More than 70% of leg ulcers are caused by venous diseases, and their prevalence increases with age. Venous leg ulcers account for most chronic lower-limb wounds observed in primary care, underscoring ...

The popliteal lymph nodes lie in the tissues behind a person’s knee. Infections and autoimmune conditions can cause them to swell. It is rare for cancer to affect the popliteal lymph nodes. According ...

The number of surgeries in the United States rises each year, with over 92 million performed in 2024. 1 For many patients, surgery is only half the battle. Managing pain afterward is often the greater ...

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

Popliteal cysts are common lesions, primarily characterized by soft tissue swelling, which may occasionally present with calcifications or small osteochondromas, and can rarely lead to restricted ...

Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement agreement with Fresenius, Jiangsu Hengrui Pharmaceuticals and eVenus ...